Beyond Air, Inc.

Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company headquartered in Garden City, New York. The company is dedicated to leveraging the therapeutic potential of nitric oxide (NO) to improve patient outcomes across various medical conditions. Its core mission revolves around developing innovative, cylinder-free NO generation and delivery systems that offer a more efficient, safer, and environmentally friendly alternative to traditional methods.

The company's flagship product is LungFit® PH, an FDA-approved system for the treatment of term and near-term neonates with hypoxic respiratory failure (PPHN). This system generates nitric oxide from ambient air, eliminating the need for cumbersome high-pressure gas cylinders. Beyond Air is also advancing its LungFit® PRO and LungFit® GO systems through clinical trials for the treatment of severe respiratory infections in both hospital and home settings, including viral community-acquired pneumonia and nontuberculous mycobacteria (NTM). Furthermore, through its affiliate Beyond Cancer, Ltd., the company is exploring ultra-high concentrations of NO for pre-clinical oncology applications, and its subsidiary NeuroNOS is engaged in a pre-clinical program for autism spectrum disorder and other neurological conditions.

In recent developments, Beyond Air appointed Robert Goodman as its new CEO in March 2026, succeeding Steve Lisi, signaling a strategic focus on accelerating market adoption and commercial growth. The company has expanded the commercial reach of LungFit® PH through agreements with national Group Purchasing Organizations (GPOs), significantly increasing its presence in U.S. hospitals. Beyond Air has also secured market authorizations for LungFit® PH in Australia and the European Union, broadening its international footprint. The company reported a 105% year-over-year revenue increase in fiscal Q3 2026, underscoring its commercial momentum and market positioning as a disruptor in nitric oxide therapy.